[
    [
        {
            "time": "",
            "original_text": "百克IPO急扩产品，单款疫苗扛九成收入，市场天花板见顶，自研太慢或开启收购",
            "features": {
                "keywords": [
                    "百克IPO",
                    "扩产",
                    "疫苗",
                    "九成收入",
                    "市场见顶",
                    "自研",
                    "收购"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "百克IPO急扩产品，单款疫苗扛九成收入，市场天花板见顶，自研太慢或开启收购",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]